Search results
Results From The WOW.Com Content Network
Timolol is a beta blocker medication used either by mouth or as eye drops. [ 3 ] [ 5 ] As eye drops it is used to treat increased pressure inside the eye such as in ocular hypertension and glaucoma . [ 3 ]
Dorzolamide/timolol, sold under the brand name Cosopt among others, is a medication used to treat high pressure inside the eye including glaucoma. [3] [5] [6] It is a combination of dorzolamide hydrochloride and timolol maleate. [3] It may be used when a beta blocker, like timolol, is not sufficient alone. [7] It is used as an eye drop. [3]
Two prospective, randomized, double-blinded, phase III clinical trials were conducted at 53 sites in the United States to compare the IOP-lowering efficacy and safety of 0.2% brimonidine tartrate/0.5% timolol maleate fixed combination twice daily with 0.2% brimonidine tartrate three times daily or 0.5% timolol maleate twice daily in patients ...
[4] [5] It is also available in the fixed-dose combination medication brimonidine/timolol along with timolol maleate. [6] Common side effects when used in the eyes include itchiness, redness, and a dry mouth. [4] Common side effects when used on the skin include redness, burning, and headaches. [5]
Travoprost/timolol, ... It contains travoprost and timolol maleate. [4] It was approved for medical use in the European Union in April 2006. [4] References
In people with ocular hypertension (IOP ≥21 mm Hg) including open-angle glaucoma, treatment with latanoprost reduced IOP levels by 22 to 39% over 1 to 12 months’ treatment. Latanoprost is more effective than timolol 0.5% twice daily in 3 of 4 large (n = 163 to 267) randomised, double-blind trials. Latanoprost demonstrated a stable long-term ...
Topical apraclonidine can also decrease IOP in glaucoma patients by increasing trabecular outflow, in a similar way to clonidine, [1] but without the cardiovascular side effects. Apraclonidine has been compared with other treatments such as brimonidine and pilocarpine in preventing IOP spikes after laser trabeculoplasty . [ 2 ]
These side effects may occur in as many as 90% of men treated with bicalutamide monotherapy, [29] but gynecomastia is generally reported to occur in 70 to 80% of patients. [30] In the EPC trial, at a median follow-up of 7.4 years, breast pain and gynecomastia respectively occurred in 73.6% and 68.8% of men treated with 150 mg/day bicalutamide ...